Related Experiment Video

Updated: Jul 22, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.1K

Real-world effectiveness of abrocitinib treatment in patients with difficult-to-treat atopic dermatitis

J I Olydam1, A R Schlösser1, P Custurone1

  • 1Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands.

Journal of the European Academy of Dermatology and Venereology : JEADV
|July 21, 2023
PubMed
Abstract

Insights

Abrocitinib effectively treats moderate-to-severe atopic dermatitis (AD) in real-world settings, even for patients who failed other advanced therapies. This JAK-1 inhibitor significantly reduces disease severity and itch, demonstrating its value in difficult-to-treat cases.

Area of Science:

  • Dermatology
  • Pharmacology
  • Clinical Research

Background:

  • Abrocitinib is a JAK-1 selective inhibitor approved for moderate-to-severe atopic dermatitis (AD).
  • Real-world data on abrocitinib for patients with prior advanced systemic therapy is limited.
  • Understanding its effectiveness in difficult-to-treat AD populations is crucial.

Purpose of the Study:

  • To assess the real-world effectiveness and safety of abrocitinib in patients with difficult-to-treat AD.
  • To evaluate outcomes in a standard care setting for patients with a history of advanced systemic treatments.

Main Methods:

  • Prospective, observational, single-center study.
  • Inclusion of AD patients initiating abrocitinib between April 2021 and December 2022.
  • Assessment of effectiveness via clinician- and patient-reported outcomes and evaluation of adverse events.

Main Results:

  • Forty-one patients were included, with 73.2% having prior treatment failures on targeted therapies (JAK inhibitors, biologics).
  • Abrocitinib showed significant reductions in EASI scores (p < 0.001) and NRS itch (p < 0.001) over a median follow-up of 25 weeks.
  • Common adverse events included gastrointestinal issues (27.6%), acne (20.7%), and respiratory infections (17.2%); 39% discontinued treatment.

Conclusions:

  • Abrocitinib demonstrates effectiveness in managing moderate-to-severe AD in daily clinical practice.
  • The drug is a viable option for patients with difficult-to-treat AD, including those unresponsive to other targeted therapies.
  • Real-world data supports abrocitinib's role in advanced AD management.

More Related Videos

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.2K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.0K

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
174
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
153
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
50